Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
Authors
Keywords
Epacadostat, IDO1, Immune checkpoint inhibition, Ipilimumab, Melanoma
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-20
DOI
10.1186/s40425-019-0562-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-Analysis
- (2018) Cheng-Peng Yu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer
- (2015) Yong Wha Moon et al. Journal for ImmunoTherapy of Cancer
- C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review
- (2015) Shiva Shrotriya et al. PLoS One
- The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells
- (2014) Xian-Feng Wang et al. CELLULAR IMMUNOLOGY
- Vascular cell adhesion molecule-1 (VCAM-1)-An increasing insight into its role in tumorigenicity and metastasis
- (2014) Martin Schlesinger et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
- (2011) Kristine H. Allin et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
- (2011) Reinhart Speeckaert et al. EUROPEAN JOURNAL OF CANCER
- Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages
- (2011) Q. Zhao et al. JOURNAL OF IMMUNOLOGY
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
- (2010) H. K. Koblish et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started